瑞舒伐他汀联合非诺贝特治疗2型糖尿病合并高脂血症的疗效观察

Effect of Rosuvastatin Combined with Fenofibrate on Type 2 Diabetes Mellitus Complicated with Hyperlipidemia

目的:探讨瑞舒伐他汀与非诺贝特联合治疗2型糖尿病合并高脂血症的疗效中的效果。方法:收集我院2014年9月至2016年9月入院的80例2型糖尿病合并高脂血症患者,随机分为两组,对照组40例患者采用单独瑞舒伐他汀治疗,实验组40例患者则采用瑞舒伐他汀联合非诺贝特治疗,比较两组患者总体疗效与治疗前后血脂水平。结果:对照组患者治疗总有效率为85.5%;实验组患者总有效率为97.5%,实验组总有效率高于对照组,且差异有统计学意义(P<0.05)。结论:瑞舒伐他汀联合非诺贝特治疗2型糖尿病合并高脂血症具有良好的治疗效果,治疗有效率有所提高,降低了低密度脂蛋白胆固醇等指标,改善血脂水平,且安全性较高,为临床研究提供理论依据。

Objective： To investigate the efficacy of rosuvastatin combined with fenofibrate in the treatment of type 2 diabetes with hyperlipidemia.Methods： 80 patients with type 2 diabetes mellitus complicated with hyperlipidemia enrolled in our hospital from September 2014 to September 2016 were randomly divided into two groups.40 patients in the control group were treated with rosuvastatin alone.The experimental group 40 Patients were treated with rosuvastatin combined with fenofibrate,and the overall efficacy was compared between the two groups before and after treatment.Results： The total effective rate was 85.5% and 97.5% in the control group and experimental group.The total effective rate in the experimental group was higher than that in the control group,and the difference was statistically significant （P〈0.05）.Conclusion： Risuvastatin combined with fenofibrate has a good therapeutic effect in the treatment of type 2 diabetes mellitus with hyperlipidemia.The effective rate of treatment is improved,and low fat lipoprotein cholesterol is reduced,and the level of blood lipid is improved and the safety is higher,which provide a theoretical basis for clinical research.